Multicenter phase II trial of weekly-paclitaxel and oral capecitabine combination therapy for metastatic breast cancer
Phase 2
- Conditions
- metastatic breast cancer
- Registration Number
- JPRN-UMIN000000603
- Lead Sponsor
- Saitama Breast Cancer Clinical Study Group (SBCCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. severe complication 2. The brain metastasis which possesses condition 3. Past history of allergic reaction 4. Past history of allergic reaction to cremophor EL (polyoxyethylated castor oil) or polysorbate 5. which has the use history of taxane or 5' DFUR or capecitabine (but the case, after taxane is prescribed in adjuvant or neo ajuvant 6months or more has elapsed, is the register possible not in addition to 1 regimen). 6. Peripheral neuropathy >= grade 2 in prior chemotherapy 7. Pregnant or lactating women 8. Doctor's decision for exclusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method